AXON — Earnings Preview

Company

Axon Enterprise, Inc.

Ticker

AXON (NASDAQ)

Upcoming Earnings Date

August 5, 2026 (After Market Close)

Reporting Period

Q2 2026 (Quarter ended June 30, 2026)

Preparation Date

August 4, 2026

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus revenue of ~$876M implies ~31% YoY growth, a step-down from Q1's 34%, and management's raised full-year guidance of 30–32% growth leaves room for upside; the single biggest swing factor is whether ARR and bookings momentum (particularly counter-drone and AI Era Plan) continues to accelerate or shows any sign of lumpiness.

Heading into Q2 2026, the bar for AXON looks achievable but not easy: consensus sits at ~$876M in revenue and ~$1.78–1.79 in adjusted EPS, both implying a modest deceleration from Q1's blowout print, yet management's raised full-year guidance of 30–32% growth effectively requires Q2–Q4 to average roughly 29–31% — a range the company has comfortably exceeded for nine consecutive quarters. Management's tone on the Q1 call was the most confident in recent memory, with CEO Patrick Smith calling Q4 2025 and Q1 2026 the company's best two consecutive quarters in history, and CFO Brittany Bagley explicitly flagging that software/services ARR step-ups would begin showing in Q2 revenue — a direct forward signal. Estimate revisions have been modestly positive since the Q1 print, with Q2 revenue consensus rising from ~$876M to ~$876M (roughly flat) and full-year consensus holding near $3.67B, suggesting the street is not yet pricing in the full upside from counter-drone (bookings up 500% YoY in Q1), AI Era Plan (bookings up 140% YoY), and the $40M telecom enterprise deal closed in April. The stock has surged ~57% since the Q1 earnings date (indexed to 100 on May 6), dramatically outperforming ITA (+12%) and SPY (+5%), driven by the Trump/ICE contract narrative, two new board appointments (Dell strategy chief and poolside AI co-founder), and $30.9M in ICE body camera orders awarded in July — meaning a meaningful portion of the upside is already priced in at ~80x forward P/E. The wildcard heading into the print is the pending $220M ICE TASER contract: if awarded or advanced before or alongside the print, it could be a significant positive catalyst; if stalled (as current reporting suggests), the market may look past it, keeping focus squarely on organic ARR and bookings trajectory.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar — ~31% revenue growth vs. management's 30–32% full-year guide — but ARR is the bigger swing factor: consensus at ~$1.59B implies ~34% YoY growth, and any acceleration above that (driven by AI Era Plan and counter-drone attach) would be the clearest signal of durable momentum.

Table 1 — Q2 2026 Current Quarter Snapshot

KPI

Q1 2026 Actual

Q2 2025 Actual (Prior Year)

Q2 2026 Consensus Estimate

YoY Change

FY 2026 Guidance

Consensus vs. Guidance

Revenue ($M)

$807.3M

$668.5M

$875.9M

+31.0%

30–32% growth (~$3.64–$3.71B)

~Midpoint

ARR ($B)

$1.493B

$1.183B

$1.589B

+34.3%

~$1.80B (FY end)

N/A (quarterly metric)

Adj. EPS (Diluted)

$1.61

$2.12

$1.78

-16.0%

~$7.63 (FY)

~Midpoint

Adj. EBITDA ($M)

$201.6M

$171.6M

$221.0M

+28.8%

25.5% margin (~$939M FY)

~Midpoint

Adj. EBITDA Margin

24.97%

25.67%

25.24%

-43 bps YoY

25.5% for FY 2026

~In line

Gross Margin (Adj.)

61.55%

63.27%

62.11%

-116 bps YoY

~62.1% (FY)

~In line

Software & Sensor Revenue ($M)

$474.7M

$375.6M

$507.6M

+35.1%

~$2.09B (FY)

N/A (segment)

TASER Weapons Revenue ($M)

$354.5M

$292.2M

$273.6M

-6.4%

~$1.14B (FY)

N/A (segment)

Future Contracted Bookings / RPO ($B)

$14.3B

$10.7B

$14.4B

+34.6%

~$18.5B (FY)

N/A (bookings metric)

Free Cash Flow ($M)

-$54.6M

-$114.7M

$99.1M

N/M

~$450M (FY guide)

~$420M FY cons. vs $450M guide

Sources: Visible Alpha Consensus and Actuals Data. Q2 2026 consensus as of August 4, 2026. Note: TASER Weapons revenue consensus of $273.6M implies a YoY decline vs. Q2 2025's $292.2M, reflecting the lumpiness of large TASER deals and the mix shift toward software; this is not a demand concern given Q1 2026 TASER revenue of $354.5M was exceptionally strong. Adj. EPS YoY decline reflects higher share count and investment spending, not operational deterioration.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Revenue & ARR)

Quarter

KPI

Reported

Consensus

Surprise %

Result

Q1 2026

Revenue

$807.3M

$778.6M

+3.7%

BEAT

Q1 2026

ARR

$1.493B

$1.437B

+3.9%

BEAT

Q4 2025

Revenue

$796.7M

$756.2M

+5.4%

BEAT

Q4 2025

ARR

$1.347B

$1.338B

+0.7%

BEAT

Q3 2025

Revenue

$710.6M

$705.2M

+0.8%

BEAT

Q3 2025

ARR

$1.252B

$1.224B

+2.3%

BEAT

Q2 2025

Revenue

$668.5M

$641.0M

+4.3%

BEAT

Q2 2025

ARR

$1.183B

$1.140B

+3.8%

BEAT

Q1 2025

Revenue

$603.6M

$587.0M

+2.8%

BEAT

Q1 2025

ARR

$1.104B

$1.041B

+6.1%

BEAT

Q4 2024

Revenue

$575.1M

$566.7M

+1.5%

BEAT

Q4 2024

ARR

$1.001B

$943.6M

+6.1%

BEAT

Q3 2024

Revenue

$544.3M

$525.2M

+3.6%

BEAT

Q3 2024

ARR

$885M

$897.3M

-1.4%

MISS

Q2 2024

Revenue

$503.2M

$478.2M

+5.2%

BEAT

Q2 2024

ARR

$850M

$859.8M

-1.1%

MISS

Pattern: AXON has beaten revenue consensus in 8 of the last 8 quarters with an average surprise of ~3.4%; ARR has beaten in 6 of 8 quarters, with the two misses (Q2 and Q3 2024) both minor and followed by strong re-acceleration. The consistent revenue beat pattern sets a high bar for the stock to react positively on a mere in-line print — the market will likely need a beat plus raised guidance to drive further upside from current elevated levels.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year revenue guidance at Q1 earnings (to 30–32% from 27–30%) and held EBITDA margin guidance at 25.5% — no post-earnings guidance revisions have been issued since May 6, so the Q1 call remains the baseline; tone has been consistently bullish with no signs of caution.

Metric

Initial Guidance (Q1 2026 Earnings Call, May 6, 2026)

Revised Guidance

Current Consensus

Note

FY 2026 Revenue Growth

30–32% YoY (raised from prior 27–30%)

~$3.67B (+30.0% YoY)

Raised at Q1 earnings; no post-earnings revision. Consensus at low end of guidance range.

FY 2026 Adj. EBITDA Margin

25.5% (unchanged from prior guidance)

~25.6%

Held steady despite revenue raise; H2 operating leverage expected to offset H1 investment spending.

FY 2026 Free Cash Flow

~$450M (new disclosure at Q1 earnings)

~$420M

First-ever FCF guidance; consensus ~$30M below guide, suggesting street skepticism on inventory normalization.

ARR (FY 2026 Exit)

~$1.80B implied (35%+ YoY growth trajectory)

~$1.80B

Consensus aligned with management trajectory; Q2 step-up to ~$1.59B is the key near-term test.

Bookings Growth

High-30s% growth expected for FY 2026; quarterly lumpiness flagged explicitly

N/A (not directly tracked by consensus)

Management flagged growing volume of nine-figure deals causing uneven quarterly patterns; Q2 bookings lumpiness is a known risk.

Long-Term (2028) Adj. EBITDA Margin

28% target (unchanged)

~26.8% (FY 2027 consensus)

2028 target reiterated; FY 2027 consensus of ~26.8% implies the street believes in the margin expansion path.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since the Q1 print — Q2 revenue consensus is essentially flat vs. the post-Q1 baseline, and FY 2026 consensus is tracking near the midpoint of guidance; the gap between FCF guidance ($450M) and consensus (~$420M) is the most notable divergence, suggesting the street is not fully crediting management's inventory normalization narrative.

KPI (Period)

Estimate ~5 Days Post Q1 Earnings (as of May 13, 2026)

Current Consensus (Aug 4, 2026)

Estimate Δ (%)

Initial Guidance (Q1 Call)

Current Guidance

Guidance Δ

Consensus vs. Guidance (%)

Revenue — Q2 2026

$875.8M

$875.9M

+0.0%

30–32% FY growth (implies ~$850–$900M Q2)

Unchanged

~Midpoint of implied range

Revenue — FY 2026

$3,677M

$3,674M

-0.1%

30–32% growth (~$3.64–$3.71B)

Unchanged

~Low end of range

ARR — Q2 2026

$1,589M

$1,589M

0.0%

~$1.80B FY exit (implies ~$1.55–$1.60B Q2)

Unchanged

~In line with trajectory

ARR — FY 2026

$1,802M

$1,802M

0.0%

~$1.80B (35%+ growth trajectory)

Unchanged

~In line

Adj. EPS — Q2 2026

$1.79

$1.78

-0.6%

~$7.63 FY (implied)

Unchanged

~In line

Adj. EPS — FY 2026

$7.66

$7.63

-0.4%

25.5% EBITDA margin guide

Unchanged

~In line

FCF — FY 2026

$457M

$420M

-8.1%

~$450M (new guidance at Q1 call)

Unchanged

-6.7% below guide

Source: Visible Alpha Consensus and Actuals Data. Estimate baseline as of May 13, 2026 (5 trading days post Q1 earnings). Estimates have been remarkably stable since the Q1 print, confirming the street is comfortable with management's guidance framework. The FCF gap is the one area where consensus is meaningfully below guidance — Q2 FCF delivery (consensus ~$99M) will be an important data point for credibility on the $450M full-year target.

5. Stock Performance

Key Takeaway: AXON has surged ~57% since Q1 earnings (May 6, 2026) vs. ITA +12% and SPY +5% — the outperformance is driven by a combination of multiple expansion on AI/drone narrative and a series of positive catalysts (Trump/ICE contract disclosure, federal body camera orders, board appointments), meaning the stock has already priced in significant execution upside and leaves little room for disappointment.

AXON vs. ITA (Aerospace & Defense ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (May 6, 2026). AXON: +57.4% | ITA: +12.2% | SPY: +5.1%. Source: Yahoo Finance / Stock Price Data.

Performance Narrative: AXON's post-Q1 trajectory can be broken into three phases: (1) Initial consolidation (May 6 – May 27): stock pulled back from the Q1 earnings pop (~$427 intraday high on May 7) to the low-$380s as the market digested the print and the stock's elevated valuation; (2) Re-acceleration (late May – early July): a sharp rally from ~$385 to a peak of ~$640 (July 7) driven by the Echodyne drone partnership (May 27), the Trump/ICE TASER contract disclosure (June 29–30), and broad momentum in defense tech; (3) Pullback and stabilization (mid-July – early August): stock retraced to the $490–$530 range as the ICE TASER contract remained unawarded and profit-taking set in, before recovering to ~$607 on August 5 (earnings day). The sector ETF (ITA) also performed well (+12%), reflecting broad defense tech tailwinds, but AXON's outperformance of ~45 percentage points is almost entirely idiosyncratic. At ~80x forward P/E, the stock is pricing in sustained 30%+ growth and margin expansion — any guidance cut or bookings miss would be severely punished.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Trump/ICE TASER contract narrative and the $30.9M ICE body camera orders — together they validate federal demand acceleration and drove the bulk of AXON's post-Q1 stock outperformance, though the larger $220M TASER contract remains unawarded and represents both upside optionality and headline risk.

7. Peer Commentaries — Read-Through for Q2 2026

The following peer commentaries are from the last 60 days (May–August 2026) and relate to themes directly relevant to AXON's Q2 2026 results: AI software adoption, government/public safety technology demand, drone/counter-UAS momentum, enterprise SaaS expansion, and federal budget dynamics. Only commentary about the current reporting environment (Q2 2026 conditions) is included — prior-quarter results commentary is excluded.

Datadog (DDOG) — Q1 2026 Earnings Call (May 7, 2026)

Read-Through Theme: AI software demand inflection and ARR acceleration

Palo Alto Networks (PANW) — Q3 FY2026 Earnings Call (June 2, 2026)

Read-Through Theme: AI-driven security demand, platformization, and government tech spending

ServiceNow (NOW) — William Blair Growth Stock Conference (June 3, 2026)

Read-Through Theme: Enterprise AI platform monetization and workflow automation

Booz Allen Hamilton (BAH) — Q4 FY2026 Earnings Call (May 22, 2026)

Read-Through Theme: Federal government technology spending environment and defense tech demand

CACI International (CACI) — Wells Fargo Conference (June 10, 2026) & BofA Conference (May 12, 2026)

Read-Through Theme: Counter-UAS demand, government defense tech spending, and software-defined systems

Leidos (LDOS) — Q2 2026 Earnings Call (August 4, 2026)

Read-Through Theme: Federal procurement acceleration and defense tech demand heading into H2 2026

SAIC — Q1 FY2027 Earnings Call (June 1, 2026)

Read-Through Theme: Government technology demand trends and AI integration in defense

8. Insider Transaction Activity

Key Takeaway: All open-market sales by CEO Patrick Smith are under a pre-established 10b5-1 plan — routine and not discretionary. The only notable signal is the absence of any open-market buys by insiders at current elevated price levels (~$490–$640 range during the period), and a single discretionary sale by CLO Isaiah Fields in May. The board RSU grants and tax-withholding transactions are standard compensation mechanics.

Name

Title

Transaction Type

Shares

Date

Note

Patrick W. Smith

CEO & Director

10b5-1 Planned Sale

10,000 shares

Jul 7, 2026

Pre-scheduled 10b5-1 plan; routine. Retains ~3.04M shares.

Patrick W. Smith

CEO & Director

10b5-1 Planned Sale

10,000 shares

Jun 29, 2026

Pre-scheduled 10b5-1 plan; routine. Retains ~3.05M shares.

Patrick W. Smith

CEO & Director

10b5-1 Planned Sale

20,000 shares

Jun 4, 2026

Pre-scheduled 10b5-1 plan; routine. Retains ~3.06M shares.

Isaiah Fields

Chief Legal Officer

Open Market Sale

2,000 shares

May 22, 2026

Discretionary sale (no 10b5-1 flag); relatively small vs. ~52,813 shares retained.

Eiso Kant

Director (newly appointed)

RSU Grant (Award)

600 shares

Jul 8, 2026

Initial RSU grant upon board appointment; standard compensation.

Vivek Mohindra

Director (newly appointed)

RSU Grant (Award)

600 shares

Jul 8, 2026

Initial RSU grant upon board appointment; standard compensation.

Multiple Directors (9 directors)

Board of Directors

RSU Grant (Award)

611–658 shares each

May 29, 2026

Annual director RSU grants; standard compensation. Recipients include Brown, Kalinowski, Williams, Garnreiter, Morgenfeld, Nardini, Partovi, Smith G., Fields.

Multiple Officers (7 officers)

COO/CFO, CRO, CHO, CLO, President, CPO/CTO, CAO

Tax Withholding (F-code)

743–32,796 shares each

Jun 1, 2026

Shares withheld for tax on RSU vesting; obligation-driven, not discretionary. Largest: President Isner (32,796 shares).

Source: SEC Form 4 filings via Insider Transaction Data. Summary: No open-market buys by any insider during the period. CEO Smith's sales are entirely 10b5-1 plan-driven and not a negative signal. The CLO's 2,000-share discretionary sale in May is the only non-plan, non-compensation transaction — too small to be meaningful. The absence of insider buying at current price levels (~$490–$640) is notable but not alarming given the stock's significant appreciation from early 2026 lows. New board members Kant and Mohindra received standard initial RSU grants.